PF-Atlas › Clinical Trials › ALOFT-IPF

Admilparant LPA1 Antagonist in IPF — ALOFT-IPF Phase III

Admilparant · LPA1 Antagonist · Phase 3

Registry ID
ALOFT-IPF
Phase
Phase 3
Status
Recruiting
Drug / intervention
Admilparant
Mechanism
LPA1 Antagonist
Sponsor
Bristol-Myers Squibb
Start
2023-06

About this trial

Admilparant is evaluated in ALOFT-IPF, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Bristol-Myers Squibb, targeting lpa1 antagonist. Current status: Recruiting.

View ALOFT-IPF on ClinicalTrials.gov →

Explore related

Admilparant / BMS-986278 — Treatment profileAll Admilparant trialsLPA1 Antagonist mechanismAll IPF trials
Medical disclaimer. This page summarizes public trial data for ALOFT-IPF for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.